Scott Thomas Jackson's Net Worth
$8.42 Million
Who is Scott Thomas Jackson?
Scott Thomas Jackson has an estimated net worth of $8.42 Million. This is based on reported shares across multiple companies, which include Spero Therapeutics, Inc., MACROGENICS INC, GLYCOMIMETICS INC, Celator Pharmaceuticals Inc, and Mural Oncology plc.
SEC CIK
Scott Thomas Jackson's CIK is 0001566617
Past Insider Trading and Trends
2016 was Scott Thomas Jackson's most active year for acquiring shares with 5 total transactions. Scott Thomas Jackson's most active month to acquire stocks was the month of April. 2016 was Scott Thomas Jackson's most active year for disposing of shares, totalling 10 transactions. Scott Thomas Jackson's most active month to dispose stocks was the month of June. 2016 saw Scott Thomas Jackson paying a total of $714,147.13 for 665,310 shares, this is the most they've acquired in one year. In 2016 Scott Thomas Jackson cashed out on 1,730,961 shares for a total of $41,934,397.36, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
MACROGENICS INC (MGNX) Snapshot price: $15.07
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 21
| |||
Form 4
|
∞
| 4.5K |
—
|
—
| 4.5K |
May 20
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 31
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 19
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 13
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 14
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 16
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 17
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 18
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 24
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Spero Therapeutics, Inc. (SPRO) Snapshot price: $1.55
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| +57.14% | 20K |
—
|
—
| 55K |
May 29
| |||
Form 4
| +133.33% | 20K |
—
|
—
| 35K |
Oct 5
| |||
Form 4
|
∞
| 15K |
—
|
—
| 15K |
Sep 15
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Aug 17
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Oct 27
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 23
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
GLYCOMIMETICS INC (GLYC) Snapshot price: $3.04
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 1
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 19
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 18
| |||
Form 4
|
∞
| 5.25K |
—
|
—
| 5.25K |
May 18
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 22
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 17
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Nov 27
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Celator Pharmaceuticals Inc No price found
Chief Executive Officer
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Mural Oncology plc (MURA) Snapshot price: $4.45
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4/A
|
—
|
0
|
—
|
—
|
0
|
May 30
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 30
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Dec 14
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||